Sermorelin is a 29-amino-acid synthetic peptide that mimics growth hormone-releasing hormone (GHRH)
Researchers who previously tolerated GLP-1 agonists may find that the amylin-based side effects of cagrilintide feel qualitatively different from what they experienced with retatrutide
Similarly, pregabalin enhanced the effectiveness of conventional OCD therapy and reduced the symptoms by 26% in a case series of 12 patients
Extending recommendations to all ages increased the impact to 104,000 hospitalizations (95% CI, 55,000-153,000) and 9,000 deaths (95% CI, 4,000-14,000) averted
The authors have declared that no competing interest exists
A Phase 2 study published in the New England Journal of Medicine in 2023 (Jastreboff et al.) reported substantial weight loss in participants with obesity